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Abstract
Parkinson’s disease (PD) experimental models are crucial in the assessment of possible 
therapies. Nevertheless, even though PD was one of the first neurodegenerative conditions 
to be modeled, there are limitations such as spontaneous recovery; lack of bilateral damage, 
which is a PD characteristic; animal intensive care after neurotoxin administration; and 
ultrastructural and biochemical nonspecific alterations but mostly the neurodegenerative 
time course observed in humans. In this chapter, we investigated the effects of divalent and 
trivalent manganese inhalation on rats and mice to obtain a novel PD animal model induc-
ing bilateral and progressive dopaminergic cell death. We found that after 5 or 6 months 
of inhalation, there was more than 70% decrease in the number of TH-immunopositive 
neurons, and these alterations are correlated with an evident motor performance deficits 
manifested as akinesia, postural instability, and action tremor. More interesting is the 
fact that these alterations were reverted with l-DOPA treatment, implying that the motor 
alterations are associated with nigrostriatal dopaminergic innervation, postulating new 
light for the understanding of manganese neurotoxicity as an appropriate PD experimen-
tal model. Our results are contributing to the development of a suitable PD animal model, 
reproducible, sensitive, time-efficient, and readily applicable behavioral tests.
Keywords: Parkinson’s disease experimental model, rodents, manganese inhalation, 
dopaminergic cell loss
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1. Introduction
The typical motor symptoms of Parkinson’s disease (PD) (akinesia, bradykinesia, rigidity, 
tremor, and postural abnormalities) are related to the loss of nigral dopaminergic cells and 
decay in caudate-putamen dopamine (DA) content that led to the introduction of DA replace-
ment therapy [1]. Consequently, there has been a fundamental role for PD animal models in 
developing new approaches treating this disease, in innovative treatment strategies, and in 
understanding the nature of the pathogenic processes involved in the dopaminergic neuronal 
loss [1, 2].
Several models display many of the distinctive features of the disease; however, none resem-
bles the complex chronic neurodegenerative features observed in human PD. 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) are considered as 
neurotoxicants that rapidly and selectively kill dopaminergic neurons (in 1–3 days), while in 
PD patients, the disease is progressive [3].
Emborg [4] declares that a representative animal model must present pathology and behav-
ioral manifestations that match the disease, involving its temporal path. The more the similar-
ity of a model is to PD, the bigger the predictive strength for clinical efficacy will be.
The results regarding manganese (Mn) as an experimental PD model have been studied since 
its toxicity (commonly called manganism) shares neurological symptoms with numerous 
clinical disorders frequently described as “extrapyramidal motor system dysfunction,” and, 
in particular, idiopathic PD [5–7]. Manganism is associated with high brain levels of Mn, pri-
marily in those areas known to contain high concentrations of nonheme iron, particularly the 
striatum, globus pallidus (GP), substantia nigra compacta (SNc), and subthalamic nuclei [8].
There is some disagreement on the alterations induced by Mn; while some researchers 
reported that Mn alters nigrostriatal dopaminergic levels and produces a Parkinson-like 
disorder [9–12], other authors confirmed that Mn alterations are related to different aspects 
to those associated to PD in both etiology and pathology [13, 14] especially in the remark-
able SNc dopaminergic cell conservation [15–19]. As stated by Calne et al. [5], Lu et al. [16], 
and others [20–22], the most important between these differences is the absence of clinical 
response to l-DOPA.
However, studies have reported ostensibly contradictory results on the dopaminergic effects 
of Mn (see Gwiazda et al. [23] and Guilarte [24] for review), including decrease [9, 25–28], 
increase [11, 29], both [30], or no modification [15, 31, 32] in SNc or striatum DA levels in 
Mn-exposed animals, probably indicating differences in exposure procedures on DA conse-
quences. These inconsistencies might disclose changes in the route of exposure, magnitude, 
duration, Mn compound or concentration, experimental animals’ species, age, etc., among 
investigations, revealing the complexity of Mn toxicity and suggesting that the features that 
cause the toxicity are not entirely recognized.
It appears that lesser dosages of Mn augmented DA and its metabolite concentrations, 
whereas the inverse was detected with more significant Mn concentrations [30, 32]. Similarly, 
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it has been proposed that higher Mn dosages can drastically accelerate DA and other catechol-
amine oxidation, which concomitantly intensify reactive oxygen species formation of [33–35].
It seems that both trivalent and divalent Mn can be carried to the CNS through the brain 
barriers [36, 37]. Mn2+ is transferred into brain choroidal epithelial and capillary endothelial 
cells through nramp2 (DMT-1) or by divalent cation transporter DCT-1 [38]. On the other 
hand, trivalent Mn bound to transferrin is transported across the brain barriers via the recep-
tor-mediated endocytosis [37]. Mn is then liberated into the endothelial cells by endosomal 
acidification [21], then is transported to the abluminal cell exterior for release into the extracel-
lular fluid. Finally, it is delivered to the glial cells and neurons, for usage and storage [39]. It 
has been demonstrated that Mn inhibits complex I in the mitochondria altering the oxidative 
phosphorylation process. Also, it appears that trivalent Mn is more effective in inhibiting 
complex I than divalent Mn [40–43] and accelerating ferrous iron oxidation. Mn3+ increased 
facility to provoke oxidative stress has been established in rats treated with either Mn chloride 
[MnCl
2
 (Mn2+)] or Mn acetate [Mn(OAc)
3
 (Mn3+)] [41]; these researchers state that 1–1000 μM 
MnCl
2
 induced increased reactive oxygen species in striatum, while Mn(OAc)
3
 produced 
comparable results at significantly lower dosages (1–100 μM). Therefore, the Mn valence and 
metabolism appear to determine its toxicity.
Thus, since it has been suggested that trivalent Mn is more effective in producing oxidative 
stress and divalent Mn requires Mn3+ to induce oxidation and that there is an interaction 
between the two Mn compounds, this study examines Mn2+/Mn3+ mixture inhalation effects 
on rats and mice to produce a unique PD experimental model provoking SNc dopaminer-
gic cell death, progressive and bilateral, associating those changes with motor alterations. 
Moreover, we sought to determine if after Mn inhalation the motor alterations improve with 
l-DOPA treatment to ensure that the alteration’s origin is dopaminergic.
2. Methods
Animals: 45 CD-1 male mice weighing 33 ± 2 g and 45 male Wistar rats weighing 180 ± 10 g 
were individually housed in hanging plastic cages under controlled light conditions (12 h 
light/dark regime) and fed with Purina Rodent Chow and water ad libitum (except the days 
of reaching task evaluation). The animals were weighed daily. The experiment was done 
according to the NIH Guide for the Care and Use of Laboratory Animals (No. 80-23 1996), 
Guide for Care and Use of Laboratory Animals certificated by SAGARPA-Mexico (NOM-062-
ZOO-1999, Mexico) and approved by the Institutional Committee of Animal Care (UNAM). 
We made all attempts to reduce the number of rodents used and their distress.
2.1. Motor behavior
Before Mn exposure, all rodents were taught and trained for motor performance. Assessment 
and training were accomplished through the lighted part of the cycle, at the same hour every 
day. For the reaching task, the animals were kept without food to 90% of average body weight 
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for 24 h and received controlled quantities of food pellets once a day to sustain body weight 
and deprivation state. Behavior analyses were conducted the days the animals did not inhale. 
Each animal was tested once a week, a different day for each test.
2.2. The reaching task
The mouse reaching box was 19.5 cm × 8 cm and 20 cm high. A 1-cm vertical slot ran up the 
front of the box. A 0.2-cm-thick plastic shelf was displayed 1.1 cm from the floor on the box 
front. The rat-reaching box was 30 cm × 15 cm and 20 cm high. As for the mice box, this one 
has a 1-cm wide and narrow opening that ran up the front of the box. About 20-mg food 
pellets were positioned near the slot. Animals were habituated for 1 week by introducing 
them in the cages for 10 min. Pellets were initially reachable on the box floor and then within 
a short distance on the shelf. Food pellets were progressively raised from the box floor and 
positioned beyond the shelf (1 cm) until the rodents were obligated to retrieve the pellet with 
their preferred forelimb. According to Whishaw et al. [44], the pronation of the paw medially 
allows the mouse/rat to catch the food pellet with the forelimb and not with their tongue. The 
animals were independently trained and permitted to grasp with their preferred forelimb the 
pellets [44]. Each animal grasped for 20 food pellets each trial during the evaluating period. 
A successful reach was scored when the animal was able to retrieve with its forelimb and eat 
a pellet. When the pellet was knocked off the shelf or pulled into the chamber and dropped 
through the floor grating were scored as a failure [45]. The qualitative evaluation comprised 
the analysis of the “reaching performance”: the posture, limb extension, aim, paw supination-
pronation during grasping, and the pellet released into the snout.
2.3. The beam-walking task
This test evaluates the rodents’ skills to traverse a narrow beam (3 mm) to reach an enclosed 
safety platform [46]. The mice apparatus is constructed by an elevating surface of a 
10 × 100 cm × 3 mm wood beam 75 cm above the floor with two supports by 15° inclination. 
Rat’s beam measured 2 m long and was elevated to a height of 1 m above the ground with 
wood supports with 15° inclination. A home box is situated near the end of the beam. On 
training days (4 days), each mouse/rat was positioned at the start of the beam with no inclina-
tion (four tests each day). When the animals traversed the apparatus in 20 s, they performed 
two more trials with the beam inclined. Mice were allowed up to 60 s and rats 120 s to traverse 
the wooden beam. The latency to cross the beam was recorded for each trial.
Video recording: the different trials were recorded with a Sony camcorder. The video camera 
was placed orthogonally to the reaching box to analyze the animal’s behavior. Demonstrative 
motionless captures were taken from the video recordings with the Final Cut Pro X for Mac.
Neurological evaluation: Tremor and bradykinesia were assessed by inspection of Mn-exposed 
compared with control animals during the performance of the two tests.
2.4. Manganese inhalation
Afterward, two groups were formed: one group was exposed to deionized water (control 
groups; n = 20), while the second group (n = 20) was exposed to the mixture of chloride (MnCl
2
) 
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0.04 M and acetate (Mn(OAc)
3
) 0.02 M (Sigma-Aldrich, Co. Mexico). Inhalations were done as 
described by Avila-Costa et al. [47]. The animals were positioned in an acrylic chamber. Mn 
exposure was accomplished in locked acrylic boxes (35 cm × 44 cm and 20 cm high) attached 
to an ultra-nebulizer (Shinmed, Taiwan), with 10 l/min constant flux. The ultra-nebulizer 
produces 0.5–5-μm range droplets. A vapor was placed on the other side of the box with 
a sodium bicarbonate mixture to trap the residual metal. During inhalations, the rats/mice 
were examined continuously for respiration frequency, regularity, and depth. The inhalation 
chamber was monitored continuously for oxygen levels, temperature, and Mn concentration.
Based on the results found in the behavioral evaluations, we sacrifice the animals after being 
exposed to 40 (mice) and 72 (rats) inhalations (5/6 months of exposure) under deep anesthesia 
with sodium pentobarbital lethal dose IP (0.2 mg). Thus, when evident motor alterations were 
observed, twenty mice/rats were sacrificed (ten controls and ten Mn-exposed), anesthetized 
with sodium pentobarbital, and perfused via the aorta with phosphate buffer saline (0.1 M 
pH 7.4) containing 4% paraformaldehyde. The brain was removed and positioned in fixative 
solution for 2 h and processed for tyrosine hydroxylase (TH) and NeuN immunocytochemis-
try (five control and five Mn-exposed brains).
Later, the rest of the animals continued the Mn inhalation. Five were treated orally with 
7.5 mg/kg l-DOPA (Sinemet [Carbidopa-L-DOPA 25/250]) every day during 2 months, five 
were reserved for the equivalent time but with no treatment, and five controls were kept for 
the same time and then sacrificed for further analysis; the motor behavior performance was 
assessed every week.
Additionally, the fresh tissue of other 10 control and 10 exposed animals, after 40 inhalations 
(mice) and after 72 inhalations (rats), was obtained to determine the concentrations of DA by 
HPLC in the striatum, SNc, and GP.
2.5. Sample preparation and immunohistochemistry
Tissue samples were serially sectioned at a thickness of 50 μm on a vibrating microtome 
(Pelco 101, Ted Pella Inc., Mexico) within the mesencephalon for TH and GP and striatum for 
NeuN immunocytochemistry. TH (Chemicon International, Inc., CA, USA, 1:1000) and NeuN 
immunostaining (Chemicon International, International, Inc., CA, USA, 1:200) with the ABC 
detection technique (Vector Lab, MI, USA) was performed for the cell analysis. All images were 
captured using an Optiphot 2 Nikon microscope. Images were analyzed using ImageJ software. 
The number of TH+ cells was calculated rostrocaudally through the SNc and ventral tegmental 
area (VTA) in nearby segments. The SNc was manually delineated to trace the region of inter-
est (ROI) at low magnification (4×). The TH-positive cell number was calculated at the level 
of the third cranial nerve, within a 100-mm counting area at 40× only within this defined ROI 
[48, 49]. NeuN cell count of striatum and GP was done using 40× objective in seven sections 
per animal at 0.70 anterior, 0.48 mm posterior to bregma for dorsomedial striatum, and 0.80 
anterior and 0.92 mm posterior to bregma for ventrocaudal GP according to [50] for rats and at 
rostrocaudal levels 0.86 anterior to 0.50 mm posterior to bregma for dorsomedial striatum and 
0.62 anterior to 0.98 mm posterior to bregma for ventrocaudal GP according to [51] for mice, in 
a 11,550 and 3300 mm2 counting area, respectively. It should be noted that both dorsomedial 
striatum and ventrocaudal GP receive the maximum dopaminergic innervation [52, 53].
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2.6. Mn concentrations
The Mn concentration in the inhaling box was calculated by placing a filter at the gap of the 
inhaling chamber during the whole inhalation time; the flow rate was constant (10 l/min). 
After each exposure, the filter was detached and weighed; the metal concentration was calcu-
lated with a graphite furnace atomic absorption spectrometer (Perkin Elmer Mod. 3110, CT, 
USA). We analyzed six filters for each inhalation [54]. At the end of the experiment, rat/mice 
serum Mn levels were also estimated by graphite furnace atomic absorption spectrometry.
2.7. Dopamine concentrations
SNc, striatal, and GP DA contents were obtained after 5 months, for mice, and after 6 months 
for rats of Mn inhalation as described by [55]. Briefly, five controls and five Mn-exposed mice 
and five controls and five Mn-exposed rats were anesthetized and decapitated, and with a 
stereoscopic microscope, the tree structures were obtained. The tissue was homogenized 
in perchloric acid with 100 μl per brain. Then, the tissue was centrifuged (300 PSI, 2 min, 
Airfuge centrifuge, Beckman, Fullerton, CA, USA) and the supernatants filtered (0.22-μm 
membranes, Millipore, Bedford, MA, USA). The resulted tissue was resuspended, and by 
Bradford method, we performed the protein determination as reported elsewhere [56]. DA 
levels in 10 μl of supernatant were determined through HPLC reverse phase system attached 
to an electrochemical detector (BAS; West Lafayette, IN, USA). Results were analyzed using 
the Peak II integration software (SRI Instruments; Torrance, CA, USA). DA concentration is 
shown as pg./μg protein.
2.8. Statistical analysis
Unpaired t-test was used to analyze the number of TH and NeuN-positive cells. Repeated 
measures ANOVA analyzed motor behavior tests; post hoc comparisons were performed 
with Tukey’s test. Group differences were established as statistically significant when p < 0.05. 
Statistical analysis was done using GraphPad 7 for Mac Software (San Diego, CA).
3. Results
After 5 (mice)/6 (rats) months of exposure, neither clinical alterations nor significant weight 
changes were detected in the exposed animals compared with controls.
3.1. Manganese concentrations
The average Mn concentration detected in the chamber filters was of 2676 μg/m3 during the 
whole experiment. The average Mn concentration in serum of exposed mice was 30 ± 5 μg/l; 
control mice serum concentration of Mn was 0.05–0.12 μg/l. The average Mn concentra-
tion in serum of exposed rats was 45 ± 5 μg/l; control rat’s serum Mn concentration was of 
0.05 ± 0.12 μg/l.
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3.2. Single-pellet reaching task
The task includes the accomplishment of motor sequences, beginning with smelling a food 
pellet forward-facing the reaching slot, lifting the arm, adapting position to project the limb 
across the narrow slot to the food pellet, and taking the food (Figure 1).
Mice and rats were presented with 20 food pellets. Figure 2 displays the success reaches 
throughout the experiment. Repeated measures ANOVA established a substantial effect of 
Mn-exposed groups since eight inhalations (p < 0.001). Mice/rats were similar in their skill to 
recover the pellets before Mn exposure, but Mn inhalation occasioned significant alterations 
in both number of successful recoveries (p < 0.001) and precision in both mice (Figure 2A) 
and rats (Figure 2B); however, with l-DOPA treatment, the animals recover their functioning 
when compared to the non-treated ones, like the control groups’ performance (p < 0.001). 
Control animals were steady during the entire experiment and were notably better than 
Mn-exposed animals (Figures 1 and 2AB).
The qualitative assessment showed postural swing and deficiencies in limb extension (result-
ing in several shortened reaches), aim, and paw supination-pronation during grasping and 
release of the pellet into the slot (Figure 3A–J); both mice and rats exhibited unusual move-
ments when recovering the food after Mn inhalation. The forelimb was frequently totally 
pronated and moves laterally over the food (Figure 3F, G, and I), or the animal hits at the 
pellet (Figure 3I); some mice/rats from Mn-exposed groups displayed such behavioral altera-
tions that endured for the complete study.
Figure 1. Characteristic pictures of a control animal taken during limb moving and withdrawal. The control animals 
moved their arm throughout the slot and opened their fingers; then, supinated their paw to take the food to the snout; 
and extended their digits to release the food into the mouth.
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The Mn-exposed groups are often incapable of accurately closing the digits around the pellet 
and dragging it to the slot without lifting the paw (Figure 3F, G, and I). These animals are 
also not capable of supinating the forelimb entirely and putting the mouth into the gap to 
recover the food with their tongue (Figure 3J). When the arm is withdrawn throughout the 
gap, Mn-exposed groups repeatedly turn their body and pursuit the food with the tongue 
instead of opening their fingers and introducing the food into the snout. The non-reaching 
forelimb is occasionally placed for support when recovering the food. Post-hoc analysis on 
the group’s effect showed that at more Mn inhalations, success of retrievals was significantly 
lesser (Figure 2). These situations amazingly recover with l-DOPA treatment (Figure 2A 
and B). The treated animals adjust their posture and project the arm toward the food pellet, 
supinate and pronate the paw to obtain the food, close their digits, and drag the food to the 
snout; their motor performance with l-DOPA treatment was comparable to control groups 
(Figures 1 and 2).
Figure 2. Reaching success scores (sum of food pellets taken out of 20; mean ± SEM) of control and Mn-exposed mice (A) 
and control and Mn-exposed rats (B) in the reaching task. The Mn-exposed group is impaired since week 12; note that 
l-DOPA treatment entirely reverses the alterations (*p < 0.001 vs. control group; repeated measures ANOVA).
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3.3. Beam-walking test
During the last day of evaluation before Mn exposure, we found no significant differences con-
cerning the time in finishing the test for the controls and the Mn-exposed animals (ANOVA, 
p > 0.05). Figure 4 depicts the mean of total time to traverse the beam. Mn-exposed mice 
(Figure 4A) and rats (Figure 4B) after 10 weeks of inhalation have a significant increase in the 
time to cross the beam compared with control groups; moreover, animals exhibit limb weakness, 
akinesia, postural instability, and action tremor. Mn-exposed mice have a significant reduction 
in the time taken to traverse the beam after two, four, six, and eight Mn inhalations (Figure 4A) 
proposing hyperactivity. Afterward there is a significant increase in the time to pass and a vis-
ible presence of freezing behavior time (data not shown), compared with control mice. As for the 
rats (Figure 4B) in the beam-walking test, Mn-exposed animals increased the execution at all-
time points. While the control rats maintained an average of 20 s during the entire experiment, 
the Mn-exposed rats are slow and take more than 120 s to cross the beam after the tenth week 
(Figure 4B). This effect is completely reversed with l-DOPA treatment. Besides, all exposed ani-
mals also exhibited hind-limb weakness, delayed motor initiative (akinesia), postural instability, 
and action tremor. l-DOPA treatment reverted these motor alterations in both rats and mice.
3.4. Immunocytochemistry
3.4.1. TH immunocytochemistry
As for TH immunohistochemistry, mice (Figure 5A) exposed to 40 inhalations showed 67.58% 
decreased in the number of TH-immunopositive neurons in SNc compared to the control 
Figure 3. Illustrative still pictures of an exposed to Mn mouse (A–E) and a Mn-exposed rat (F–J). The animal approaches 
its forelimb by moving the elbow for the hand goes through the gap. As the arm moves closer to the food, the fingers 
open, and then the mouse pronates its forelimb by elbow adduction and rotates it around the wrist so that the hand is 
positioned on the top of the food. The pellet is grabbed by flexion of the fingers. The forelimb is withdrawn carrying the 
food. The animal lies on its hips to eat the pellet, which is secured by the hands. Frames (F–J) Mn-exposed rats displayed 
alterations characterized by severe postural modifications moving the forelimb obliquely throughout the gap making 
various small efforts without stretching the forelimb according to the midline of its body. The fingers are simultaneously 
adducted. The forelimb arises in front of the side or hits laterally, and the fingers do not take the food. The animal often 
pulls its forelimb across the gap and let fall the food to the floor cage chasing it with the tongue.
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animals, while there was no loss of neurons in VTA of exposed animals compared to controls 
(Figure 5A and 6). The rats showed a 75.9% loss in the number of TH immunoreactive neurons 
after 48 inhalations and, like mice, showed no neuronal loss in the VTA (Figure 5B and 6).
3.4.2. NeuN immunocytochemistry
One of the required characteristics for animal models is the neuronal specificity for cerebral 
nuclei that are affected in humans, so to determine if the Mn mixture affects other brain struc-
tures, we performed anti-NeuN immunohistochemistry, a nuclear protein neuronal specific. 
In this respect, we found no significant loss in the number of neurons in any of the analyzed 
nuclei (data not shown).
Figure 4. Mean latencies to traverse the beam (±SEM) before and after mice (A) and rats’ (B) Mn inhalation and after 
l-DOPA treatment. It is notorious that after 2, 4, 6, and 8 of Mn inhalation, the mice significantly reduce the time to 
traverse the beam and afterward showed a significant increase in the time to cross the beam compared to controls. The 
Mn-exposed rats are significantly impaired since week 10. However, when the animals received the l-DOPA treatment, 
the time was reduced drastically resembling the values of the control group (*p < 0.001 vs. control group).
Dopamine - Health and Disease68
Figure 5. TH+ cell number from the SN) and VTA. The data are depicted as the mean ± standard error. A statistically 
significant diminution in TH+ cells was observed in the SNc (*p < 0.05 unpaired t-test) of Mn-exposed mice (A) and rats 
(B) compared to controls with no changes in the VTA.
Figure 6. Characteristic TH+ immunostained from coronal sections comprising the SN and VTA of control and 
Mn-exposed animals showing the ROI which demonstrates the SNc area used for cell calculating. Note that the VTA 
contains many TH+ cells with no differences among groups and the SNc pronounced cell loss after Mn exposure (upper 
panel 4×, lower panel 10,000×).
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3.5. Dopamine concentrations
Figure 7 shows the change in DA content determined in the striatum (Str), GP, and SNc after 
5 months (mice) or after 6 months (rats) of Mn inhalation compared to controls. The average 
content in the control mice was 96.545 ± 4.8820 and 28.008 ± 12.4500 pg/μg of protein for 
Mn-exposed mice; hence, DA content declines 71 and 76% for the rat’s striatum.
4. Discussion
This research studied the fact that MnCl
2
 mixed with Mn(OAc)
3
 induces synergistic conse-
quences by affecting the dopaminergic system reducing TH+ cell number in the SNc but not 
Figure 7. The decrease in dopamine concentrations in the striatum (str), GP, and SNc after 5 months (mice A) or 6 months 
(rats B) of Mn inhalation compared to controls. Contents are expressed as percentages, which were in pg/g of protein 
(*p < 0.001 vs. control group by one-way ANOVA with post hoc comparisons).
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in the VTA and reducing DA striatal, GP, and SNc levels, in both mice and rats. We found 
significant hyperactivity after the first weeks (2–8 inhalations) in mice and, afterward, evident 
reduction and alterations in locomotor activity; the motor changes improve drastically after 
l-DOPA treatment in both species. However, rats display different vulnerability to MnCl
2
/
Mn(OAc)
3
 inhalation as they inhaled three times a week for 6 months. Nevertheless, regard-
less of the modified procedure, both species display notorious changes in motor behavior and 
a significant decrease in TH+ cells in the SNc but not in VTA. Moreover, neither of the two 
species displayed neuronal death neither in the striatum nor the GP.
4.1. Motor performance alterations
4.1.1. Single-pellet reaching task
It has been demonstrated that skilled limb movements, such as the reach to grasp, display very 
similar motor components in humans and rodents [57, 58]. PD patients are often described 
as having poor manual skills that worsen as the disease progresses [59, 60]. These patients 
experience difficulties performing tasks requiring unilateral and bilateral arm movements 
and sequential and alternating limb movements [58]. In our results, mice and rats took the 
food from the ledge without raising the forelimb and either place the mouth into the gap 
to recover the food pellet with the tongue or turn their body and chase the food with the 
mouth. Those changes could comprise impairments to basal ganglia structures responsible 
for grasping movements [61]. Our results thus demonstrate that Mn-exposed animals have 
impairment in their success in retrieving food pellets probably due to dopaminergic cell loss.
4.1.2. Beam-walking test
Both rats and mice showed extremity coordination disturbances, step length, and motor per-
formance. With longer inhalation times, the Mn-exposed groups display more trouble for 
climbing the wooden beam. The motor alterations observed here are similar with published 
results in which C57-treated MPTP exhibited impairments in limb coordination, step length, 
and motor performance after 2 weeks [62].
Qualitative examination showed that the groups which inhaled Mn mixture displayed 
postural instability, akinesia, hind-limb weakness, prolonged freezing behavior, and action 
tremor. According to this, Autissier et al. [9] described that subchronically orally exposed to 
Mn mice exhibited akinesia; this alteration was related with low striatal DA levels; Eriksson 
and coworkers [25] reported that 5 months after Mn exposure the animals developed akinesia, 
action tremor, and unsteady gait. The exposed animals lacked strength in lower and upper 
limbs, and the limb movements were uncoordinated. Furthermore, the stereotaxic injection of 
Mn3+ into the rat SNc altered the rearing behavior and the spontaneous activity [63, 64].
4.2. Immunocytochemistry
Rats and mice exposed to Mn showed severe loss of SNc TH-immunopositive cells, but not in 
VTA, GP, or striatum. Our results disagree with other reports which found no loss of dopami-
nergic neurons [11, 18, 19, 32, 65, 66] and loss of striatal and GP cells [15, 17, 19]. The disagree-
ments concerning our results and the conclusions that describe no TH+ SNc cell death and GP 
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and striatal cell loss after Mn exposure might be due to at least three causes; first, the mixture 
of two Mn compounds, which, by far, no report includes such mixture of Mn compounds. 
Agreeing to Aschner [67], it appears that the Mn toxicity degree is about its oxidation state. As 
we mentioned above, divalent Mn might be oxidized to trivalent Mn by the superoxide anion 
[40], and because the electron transport chain in the mitochondria is recognized as the major 
superoxide producer in the cells, it is understood that the alterations induced by Mn are linked 
to its oxidation state [40]. It has been proposed that Mn3+ is more effective in producing cell 
damage [68] and Mn2+ needs the presence of Mn3+ to reach oxidation. Thus it seems that there 
is synergy between the two Mn states [43]. It also has been said that the brain is an important 
target of attack for transition metal ions, such as Mn, due to its abundant catecholamine con-
centration and the rapid oxidative metabolism catalyzed by these metals [69]. In this regard, 
it has been hypothesized that Mn interacts with catechols specific to dopaminergic neurons 
to rapidly deplete them and render such cells no longer viable [33, 40]. Thus, it is conceivable 
that Mn-induced DA oxidation results in the generation of reactive oxygen species, oxidative 
stress, and secondary cytotoxicity to dopaminergic neurons [40, 70, 71]. Numerous explana-
tions have been proposed to clarify the vulnerability of dopaminergic cells to Mn, such as 
the lack of cellular antioxidant defenses by the accumulation of the metal [72] and the dis-
ruption of mitochondrial oxidative energy metabolism [73]. Second, the concentration of Mn 
obtained in the inhalation box (2676 mg/m3) and the time of exposure (5 or 6 mo) are sufficient 
to produce motor and cell alterations. It has been suggested that Mn toxicity results, most 
often, from the chronic exposure to very high Mn dosage (>1 mg/m3) [7] and after long-term 
exposure [23]. Third, apparently the exposure method determines the delivery of Mn to the 
brain [74, 75]. Roels et al. [75] explored Mn levels in rat brains after exposing them to either to 
MnCl
2
 or MnO
2
. These compounds were given intratracheally (inhalation) or intragastrically 
(oral). This study proposed was to achieve comparable Mn concentrations in the blood and 
to reach for low oral absorption of Mn vs. the higher rate of absorption from the lung. When 
the exposition was 1.22 mg MnCl
2
/kg intratracheally once a week for 4 weeks, there was an 
increase in blood Mn concentration (68%), which also results in augmented Mn concentra-
tions in the striatum (205%) and cortex (48%) when compared to control group. Oral MnCl
2
 
administration (24.3 mg MnCl
2
/kg once weekly for 4 weeks) produced about the same blood 
Mn concentration (68% increase comparing to controls) as intratracheal Mn administration in 
the same form, but they did not find significant Mn increase in the striatum or cerebral cortex 
(22% increase versus controls). Therefore, inhaled Mn delivery seems to be more efficient than 
oral administration in increasing brain Mn levels.
Moreover, it is relevant to indicate that, while Mn exposure provoked important SNc dopa-
minergic cell death, it appears that the VTA dopaminergic cells are not affected. We do not 
have the facts yet to demonstrate whether this indicates Mn selectivity for the SNc dopa-
minergic neurons and not for the VTA cells. Nevertheless, it has been proposed that Mn 
gets into the neurons via the dopamine transporter (DAT) [76, 77] as in the case of some 
neurotoxins such as MPTP [78], 6-OHDA [79], Maneb, and Paraquat [26], where SNc cells 
are more vulnerable than VTA cells. It appears that SNc neurons and VTA exhibit different 
biochemistry, topography, and susceptibility to pathological processes [81], VTA has lesser 
DAT levels than the SNc [78, 80, 81]. Therefore it is conceivable that Mn gets into SNc cells 
via the significant volumes of DAT located in these neurons. Nevertheless, further research 
is required to settle this fact.
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4.3. Dopamine concentrations
Several studies have shown that Mn accumulates in the basal ganglia, particularly in the GP, 
the NE, and the SNc which cause neurodegeneration; Mn chronic exposure can induce simi-
lar changes to those observed in PD [82]. Patients with this disease present rigidity, tremor, 
akinesia, and postural changes. These signs reflect the SNc dopaminergic neuronal loss [83]. 
In this disease, there is a threshold; the motor symptoms appear when DA depletion in the 
striatum is about 80%, and about 60% of SNc dopaminergic neurons are lost [84]. These 
results are consistent with our data, which show that after MnCl
2
/Mn(OAc)
3
 mixture inhala-
tion, the number of TH-positive SNc neurons decreases to 63% (in mice) and 75% (in rats) 
and DA content decreases in the studied nuclei, which could explain the motor disturbances 
observed in the behavioral assessments. Thus, the significant reduction in the quantity of 
SNc TH+ neurons after MnCl
2
/Mn(OAc)
3
 exposure and the decrease of striatal DA concen-
trations described here explains the evident DA reduction and the parkinsonian symptoms. 
Therefore, we assume that the motor alterations are exclusively due to dopaminergic changes 
because l-DOPA was able to reverse those motor disturbances.
Some authors described that Mn-induced damage includes the GP [17, 19]; nevertheless, with 
our data, we can guarantee that the MnCl
2
/Mn(OAc)
3
 mixture inhalation also compromises 
the dopaminergic nigrostriatal pathway. With our results, we prove that l-DOPA treatment 
significantly recovers the motor performance alterations observed after Mn inhalation, 
implying that this motor change origin is dopaminergic. Furthermore, the alterations pro-
duced by the inhalation of Mn mixture compounds were sufficiently extensive to cause motor 
deficits such as tremor, rigidity, postural instability, and akinesia. And unlike the complete 
DA denervation produced by some neurotoxins such as 6-OHDA, which is the most fre-
quently used model, the inhalation of MnCl
2
/Mn(OAc)
3
 leaves a considerable portion of the 
nigrostriatal projection unharmed. As in early and middle stages of PD, the presence of an 
intact, functioning sub-portion of the nigrostriatal system could allow l-DOPA treatment to 
be effective.
4.4. Differences among species
It is well established that different vulnerability to neurotoxins occur among species. So, 
the best PD experimental model MPTP, in rats, is not actuality used, and the implications 
of the data obtained from this model are debatable [85, 86]. Rats injected with MPTP doses 
comparable to those employed in mice do not show any significant dopaminergic neuro-
degeneration [86, 87]. Only injections of much higher doses of MPTP (multiple applica-
tions of 30–60 mg/kg body weight) cause significant dopaminergic cell loss in rats [88]. 
Remarkably, these rats must be therapeutically pretreated, with guanethidine, to prevent 
peripheral catecholamine release and extensive mortality [86]. These findings indicate that 
rats are somewhat insensitive to MPTP. Consequently, rats are not recommended for MPTP 
research, since rats fail to develop parkinsonian characteristics, as those observed, e.g., for 
monkeys and mice [89]. The apparent insensitivity of rats to MPTP toxicity may be related 
to a species-specific metabolism of MPTP and sequestration of MPP+, which could be differ-
ent in rats compared to mice and monkeys [89]. And despite that MPTP in nonhuman pri-
mates and mice provokes a well animal PD model, a spontaneous recovery of parkinsonian 
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symptoms has been described in both monkeys [90] and mice [91] after MPTP administra-
tion, which causes concern to use this model for an assessment of long-term therapeutic 
effects. However, it has been reported that chronic administration of low doses of MPTP 
to macaques reproduces all the signs of PD and closely imitates the progressive nature 
[92]. Nonetheless, rodents are most commonly used over nonhuman primates since rodent 
models have the advantage that rats and mice are widely available. They have high repro-
ductive rates and require reduced living space, simple feeding, and drinking schedules and 
low costs [93]. Moreover, because of the economic, logistic, and ethical constraints that are 
related to experimental research in primates, primate models of PD are used in relatively 
few laboratories worldwide [94].
Furthermore, 6-OHDA model has been extensively used in rats; only scarce studies using 
mice with 6-OHDA lesions have been published. In these studies, 6-OHDA was injected 
mainly either intrastriatally [95, 96] or intraventricularly, and the mice were subjected to rela-
tively slight behavioral assessment [97]. Furthermore, Cenci and Lundblad [98] performed 
the stereotactic unilateral 6-OHDA injection in rats and mice and then treated them with 
l-DOPA and reported abnormal involuntary movements (AIMs); these researchers indicated 
that while rat and mice AIMs can be evaluated with the same parameters, there are important 
differences among the two species. Mice motor behavior is less articulate and faster than rats. 
It is, therefore, more challenging to determine mice normal and abnormal movements with 
6-OHDA model. Additionally, Iancu et al. [99] stereotactically lesioned mice SNc; they got 53 
well-lesioned animals out of 110 lesioned. The small amount of well-lesioned mice is prob-
ably due to the SNc size since in mice it is extremely small. The slight variances in the inhala-
tion procedure between species that we found here are likely because rat Mn absorption is 
a fast saturable process probably mediated by a high-affinity system [100]. Consequently, 
the rats, although with the same Mn concentrations, required more inhalations per week for 
6 months instead of 5. However, both species, cytological and behavioral alterations, were 
very similar.
5. Conclusion
Contrasting to MPTP and 6-OHDA PD models, where the alterations occur in a range of 
days or weeks, while PD in humans develops over decades [90], our PD experimental model 
induced by Mn inhalation seems to be a suitable model because the dopaminergic cell degen-
eration is bilateral and progressive and the variances among species are minimum.
It has been established [88] that an acceptable PD experimental model must have these 
features: (1) an average number of SNc dopaminergic cells at birth followed by a gradual 
selective loss of these cells in adulthood; (2) merely demonstrable and measurable motor 
alterations; (3) the model should be established at reasonably short time course to replicate 
the PD pathogenesis (about 3–6 months), which would allow for therapeutic substances and 
strategies assessment; and (4) Lewy bodies must be present. Hence, with our Mn inhalation 
model, we produce three of those characteristics. Nevertheless, further studies are needed to 
clarify if Mn exposure generates Lewy bodies and determine if the animals recover after the 
inhalation period.
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Finally, the results from this research provided essential contributions toward a better under-
standing of the mechanisms involved in nigrostriatal degeneration in PD because it is highly 
feasible and adequately simulates the neuroanatomical, neurochemical, and some of the PD 
behavioral characteristics.
In brief, the results of this research suggest that the motor alterations induced by the inhala-
tion of the combination of MnCl
2
/Mn(OAc)
3
 are related to nigrostriatal dopaminergic func-
tion, providing new light for the understanding of Mn neurotoxicity as an adequate PD 
experimental model.
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